GlaxoSmithKline | GSK - Selling And Administration Expenses


GlaxoSmithKline reported GBP2.19B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alcon AG USD 882M 19M Mar/2026
Amgen USD 1.72B 134M Jun/2026
argenx SE USD 417M 62M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Fresenius EUR 760M 17M Jun/2026
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Novo Nordisk DKK 16.31B 3.09B Jun/2026
Orion EUR 98.9M 7M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Philips EUR 1.21B 23M Jun/2026
Recordati EUR 201.58M 8.82M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026
UCB EUR 1.47B 193M Dec/2025